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Background
European SOHO is a prospective, observational study of
antipsychotic treatment in 10 European countries.
Materials and methods
Clinical effectiveness and Qol were assessed using the
Clinical Global Impression (CGI) scale and the EQVAS
instrument, respectively. The results that follow have been
calculated by analysing treatment outcomes of SOHO
patients who, from baseline to 12 months of follow-up,
had only received the same monotherapy antipsychotic
treatment (completers).
Results
Olanzapine-treated patients had higher benefit in overall
CGI improvements (mean; 95% CI) during the first 12
months, compared with risperidone (2.51, 1.16–5.44),
but not with quetiapine (1.16, 0.17–7.5) and oral typicals
(1.6, 0.24–10.8)- treated patients.
Olanzapine-treated patients had no significant differences
in EQVAS improvements during the first 12 months com-
pared with other treatments.
Discussion
During the first 12 months of treatment olanzapine
appears to have superior efficacy advantages compared
with risperidone, but not with quetiapine or typical antip-
sychotics on clinical grounds. There was no differentiation
between olanzapine and other typical and atypical antip-
sychotics regarding EQVAS score changes.
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